This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

A Look at the Breast Cancer Landscape: An Expert's Take on the Newly Approved Daiichi Sankyo Drug, ENHERTU, SGEN's tucatinib, & the Role of IO therapy

Ticker(s): D4S.F, SGEN

Who's the expert?

An oncologist who is familiar with ticatinib.

Interview Goal
This call will examine the pipeline for breast cancer drugs. We'll dig in with the expert on the potential of Daiichi Sankyo's recently approved drug ENHERTU, SGEN's tucatinib and what role IO therapy, if any, will play.

Are You Interested In These Questions?



172Days Left to Join Project

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.